Article, see p 1571 I MPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial), conducted in 18 144 participants who had recently experienced an acute coronary syndrome, demonstrated that the addition of ezetimibe 10 mg to simvastatin 40 mg, both taken daily, reduced low-density lipoprotein (LDL) cholesterol by an additional 16 mg/dL in comparison with placebo added to simvastatin 40 mg daily. This led to a 6% proportional reduction in the risk of the primary cardiovascular outcome (a composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization, or nonfatal stroke) over 6 years (hazard ratio, 0.94; 95% confidence interval, 0.89-0.99; P=0.016).
1,2
In this issue of Circulation, the IMPROVE-IT investigators present exploratory analyses that raise hypotheses about groups of patients that may derive differential benefit from ezetimibe treatment. There is a particular focus on diabetes mellitus, which was present in 27% of participants at baseline. It is suggested that the relative benefits of ezetimibe may be enhanced both in the presence of diabetes mellitus (in comparison with its absence) and, when limited to nondiabetic patients, in those at higher cardiovascular risk (in comparison with nondiabetic patients at lower cardiovascular risk). 3 The first conclusion rests on an interaction test (P=0.023) for the subgroup analysis comparing those with and without diabetes mellitus who achieved 15% and 2% reductions in the primary outcome, respectively, on ezetimibe/simvastatin versus placebo/simvastatin. 3 The second conclusion, based on an interaction test (P=0.034), rests on a further subgroup analysis, conducted in the subpopulation of IMPROVE-IT without diabetes mellitus; in this analysis, selected components of the primary outcome were used. 3 At face value, these new IMPROVE-IT results appear to have important clinical implications. However, it should be remembered that subgroup analyses from clinical trials can be unreliable, and this may be especially true when the treatment effects are small, results from the primary analyses are of marginal statistical significance, or emphasis is placed on nominally significant findings in the context of multiple such analyses. 4 Indeed 1 statistician has cautioned that "…the play of chance often produces qualitatively wrong answers in particular subgroups in trials (or in meta-analyses of trials) that could, if interpreted incautiously, lead to millions of people being treated inappropriately or untreated inappropriately." 4 To avoid such a situation occurring with ezetimibe, we should pause to reflect on these new findings and consider the likelihood that they simply represent chance.
Regarding the first hypothesis, the key question to pose is whether other available evidence provides a rationale to expect the presence of diabetes mellitus to modify the relative effects of LDL lowering with ezetimibe on cardiovascular outcomes. Important conclusions can be drawn from recent genetic studies. The Niemann-Pick C1-Like 1 (NPC1L1) gene encodes the ezetimibe target receptor, and naturally occurring polymorphisms in NPC1L1 that associate with lower LDL cholesterol also associate with lower risk of coronary heart disease. 5 In 1 major study conducted in 108 376 individuals from 14 studies in which 10 464 coronary heart disease events occurred, the group with 2.3 mg/dL lower genetically predicted LDL cholesterol based on NPC1L1 gene score was at 4.4% lower risk of coronary heart disease than the group with higher genetically predicted LDL cholesterol. It is notable that this observation was made in a population in which 94% did not have diabetes mellitus, suggesting that it is implausible that this benefit is driven by those with diabetes mellitus.
The Cholesterol Treatment Trialists' (CTT) Collaboration has shown that for each ≈40 mg/dL lowering in LDL cholesterol achieved with a statin, the incidence of major cardiovascular outcomes is reduced by 22% (0.78, 0.76-0.80). This relative benefit occurs irrespective of the presence or absence of diabetes mellitus (interaction P=0.81).
2 Diabetes mellitus also does not appear to modify the beneficial effects of LDL cholesterol lowering with inhibitors of PCSK9 (proprotein convertase subtilisin-kexin type 9). In a recent phase III placebo-controlled cardiovascular outcome trial of evolocumab, the 62 mg/ dL reduction in LDL cholesterol on evolocumab led to a 15% reduction in the incidence of the primary cardiovascular outcome (hazard ratio, 0.85; 0.79-0.92), and LDL cholesterol reductions were similar in those with and without diabetes mellitus, as were the relative effects on the primary outcome (interaction P=0.60). 6 It is also worth considering that the interaction test, already only of marginal significance (P=0.023), would tend toward being nonsignificant if the smaller time-weighted difference in LDL cholesterol among nondiabetic participants versus diabetic participants was taken into account (14 versus 17 mg/dL; P=0.03) and adjustment was made for the additional testing of >20 other subgroups presented during the primary analyses of the IMPROVE-IT data. 1 The same considerations about multiplicity hold true when considering the post hoc subgroup analyses by baseline cardiovascular risk in the subpopulation of IM-PROVE-IT without diabetes mellitus at baseline. It is also worth noting that there is no good evidence that baseline risk modifies the relative cardiovascular benefit of statins. 7 Because there is unlikely to ever be enough additional randomized data to definitively test these new hypotheses, and given the various strands of compelling genetic and randomized trial evidence suggesting that relative cardiovascular benefit is likely to be similar in those with and without diabetes mellitus, it is reasonable to conclude that ezetimibe reduces atherosclerotic cardiovascular risk through lowering LDL cholesterol irrespective of the presence or absence of diabetes mellitus. To quantify which patients might be expected to have a smaller or larger absolute benefit from ezetimibe (per unit reduction in LDL cholesterol), we would recommend classifying their risk of atherosclerotic cardiovascular disease by using a relevant and reliable risk score and then applying the relative benefits estimated by the overall IMPROVE-IT result. 1 
